Loading
A phase 1/2 trial of SG2918 in multiple myeloma, run by Hangzhou Sumgen Biotech Co., Ltd., now recruiting.
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07454187 by Hangzhou Sumgen Biotech Co., Ltd., with 40 participants planned, started 2026-04-16 and due to reach its primary completion in 2027-09-30. Interventions recorded: SG2918.
Shares Hangzhou Sumgen Biotech, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.